Advertisement

In Vitro Activities of Nine Antifungal Agents on Candida Species Isolated as Causative Agents from Clinical Materials

  • C. B. Johansson
  • S. Bilgin
  • J. Taşçioǧlu
  • G. Söyletir
  • B. Ener
Part of the Federation of European Microbiological Societies Symposium Series book series (FEMS, volume 50)

Abstract

The incidence of mycotic infection due to yeasts has increased during the last few years because of the immunosuppressive therapies, prolonged antibiotic therapy, organ transplantations, aggressive instrumentations in medicine, AIDS, etc.

Keywords

Candida Albicans Antifungal Agent Candida Species Candida Tropicalis Throat Swab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.R. Graybill, J.N. Galgiani, J.M. Jorgensen and D.A.Strandberg, Ketoconazole therapy for fungal urinary tract infections, J.Urol., 129: 68 (1983).PubMedGoogle Scholar
  2. 2.
    R. Guinet, J. Chanas, A. Coullier, G. Bonnefoy and P. Ambroise-Thomas, Fatal septisemia due to amphotericin B resistant Candida lusitaniae, J. Clin. Microbiol., 18: 443 (1983).PubMedGoogle Scholar
  3. 3.
    R.J. Holt and A. Azmi, Miconazole resistant Candida, Lancet, 1: 50 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    E.M. Johnson, M.D. Richard and D.N. Warnock, In vitro resistance to imidazole antifungals in Candida albicans, J. Antimicrob. Chemother., 13: 547 (1984).Google Scholar
  5. 5.
    R.F. Boyd and B.G. Hoerl, The pathogenic fungi, in “Basic Medi- cal Microbiology”, R.F. Boyd, ed., pp 775–813; Little, Brown and Company; Boston (1986).Google Scholar
  6. 6.
    P.D. Hoeprich and M.G. Rinaldi, Candidosis, in “Infectious Diseases”, P.D. Hoeprich, ed., pp 436–450, Harper and Row Publisher, Philadelphia (1983).Google Scholar
  7. 7.
    D. Kerridge and R.D. Nicholas, Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata, J.Antimicrob. Chemother., Supp. B, 18: 39 (1986).Google Scholar
  8. 8.
    M.R. Mc Ginnis and M.G. Rinaldi, Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing and assays of activity in biological fluids, in: “Antibiotics in Laboratory Medicine”, Second Edition, V. Lorian, ed., Williams and Wilkins, Baltimore (1986)Google Scholar
  9. 9.
    J.N. Galgiani, J. Reiser et al., Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods, Antimicrob. Agents Chemother., 31: 1343 (1987).Google Scholar
  10. 10.
    S.P. Clissold and J.V. Cutsem, Overview of the antimicrobial activity of ketoconazole, in: “Ketoconazole Today”, H.E. Jones, ed., pp. 1–18, ADIS Press Limited, Manchester (1987).Google Scholar
  11. 11.
    D.J. Drutz, Newer antifungal agents and their use, including an update on amphotericin B and flucytosine, in: “Current Clinical Topics in Infectious Disease”, J.S. Remington and M.N. Swartz, eds., pp 97–135, Mc Graw-Hill Book Company, New York (1982).Google Scholar
  12. 12.
    S.Shadomy and A. Espinel-Ingroff and R.Y. Cartwright, Laboratory studies with antifungal agents: Susceptibility test and bioassays, in: “Manual of Clinical Microbiology”, E.H. Lennette, ed., pp. 991–999, American Society for Microbiology, Washington D.C. (1985).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • C. B. Johansson
    • 1
  • S. Bilgin
    • 2
  • J. Taşçioǧlu
    • 2
  • G. Söyletir
    • 1
  • B. Ener
    • 1
  1. 1.Department of Microbiology, Faculty of MedicineMarmara UniversityHaydarpşa, IstanbulTurkey
  2. 2.Microbiology LaboratoryHaydarpşa Numune HospitalHaydarpşa, IstanbulTurkey

Personalised recommendations